epanova Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Epanova, and what generic alternatives are available?
Epanova is a drug marketed by Astrazeneca and is included in one NDA. There are seven patents protecting this drug.
This drug has eighty-four patent family members in forty countries.
The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this compound. Additional details are available on the omega-3-carboxylic acids profile page.
DrugPatentWatch® Generic Entry Outlook for Epanova
Epanova was eligible for patent challenges on May 5, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 20, 2026. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for epanova
International Patents: | 84 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 16 |
Patent Applications: | 164 |
Formulation / Manufacturing: | see details |
DailyMed Link: | epanova at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for epanova
Generic Entry Date for epanova*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for epanova
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Cleveland Clinic | Phase 3 |
Cleveland Clinic Coordinating Center for Clinical Research (C5R) | Phase 3 |
Quintiles, Inc. | Phase 3 |
US Patents and Regulatory Information for epanova
epanova is protected by seven US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of epanova is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting epanova
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET
Type A gelatin capsule containing PUFA in free acid form
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Type a gelatin capsule containing PUFA in free acid form
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HYPERTRIGLYCERIDEMIA
Type A gelatin capsule containing PUFA in free acid form
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HYPERTRIGLYCERIDEMIA
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HYPERTRIGLYCERIDEMIA
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Type A gelatin capsule containing PUFA in free acid form
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF HYPERTRIGLYCERIDEMIA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for epanova
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
Astrazeneca | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for epanova
See the table below for patents covering epanova around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 6399655 | ⤷ Try a Trial | |
China | 108524483 | 游离酸形式的Ω-3多不饱和脂肪酸的富含DPA组合物 (DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form) | ⤷ Try a Trial |
Brazil | 112014016788 | composições de ácidos graxos poli-insaturados ômega-3 em forma de ácido livre, enriquecidas com dpa | ⤷ Try a Trial |
Portugal | 825858 | ⤷ Try a Trial | |
Poland | 184085 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |